The prognostic impact of variant histology in nodular lymphocyte- predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group (GHSG)

Blood

Volumn 122, Issue 26, 2013, Pages 4246-4252

  Hartmann, Sylvia ^a   Eichenauer, Dennis A ^b   Plütschow, Annette ^b   Mottok, Anja ^c   Bob, Roshanak ^d   Koch, Karoline ^e   Bernd, Heinz Wolfram ^f   Cogliatti, Sergio ^g   Hummel, Michael ^h   Feller, Alfred C ^f   Ott, German ⁱ   Möller, Peter ^j   Rosenwald, Andreas ^c   Stein, Harald ^d   Hansmann, Martin Leo ^a   Engert, Andreas ^b   Klapper, Wolfram ^e  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Pathodiagnostic Berlin Berlin Reference Centre for Lymphoma and Haematopathology   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^j UNIVERSITY HOSPITAL ULM   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GERMANY; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNE DEFICIENCY; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

EID: 84891073765     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-515825     Document Type: Article

References (29)

1. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999;17 (3): 776-783.
2. Nogov'a L, Reineke T, Brillant C, et al German Hodgkin Study Group. Lymphocytepredominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008;26 (3): 434-439.
3. Saarinen S, Pukkala E, Vahteristo P, M?akinen MJ, Franssila K, Aaltonen LA. High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2013;31 (7):938-943.
4. K?uppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA. 1994; 91 (23):10962-10966.
5. Braeuninger A, K?uppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA. 1997;94 (17):9337-9342.
6. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337 (7):453-458.
7. Steimle-Grauer SA, Tinguely M, Seada L, Fellbaum C, Hansmann ML. Expression patterns of transcription factors in progressively transformed germinal centers and Hodgkin lymphoma. Virchows Arch. 2003;442 (3):284-293.
8. Tedoldi S, Mottok A, Ying J, et al. Selective loss of B-cell phenotype in lymphocyte predominant Hodgkin lymphoma. J Pathol. 2007;213 (4): 429-440.
9. Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008;205 (10): 2251-2268.
10. Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27 (10): 1346-1356.
11. Boudov'a L, Torlakovic E, Delabie J, et al. Nodular lymphocyte- predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocytepredominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003;102 (10):3753-3758.
12. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363 (7): 640-652.
13. Eich HT, Diehl V, G?orgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28 (27):4199-4206.
14. Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29 (32): 4234-4242.
15. Borchmann P, Diehl V, Goergen H, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial. Haematologica. 2010: 95 (suppl):A1146.
16. von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30 (9):907-913.
17. Engert A, Haverkamp H, Kobe C, et al German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikament?ose Tumortherapie. Reducedintensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379 (9828):1791-1799.
18. Nogov'a L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16 (10):1683-1687.
19. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011;118 (16): 4363-4365.
20. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339 (21): 1506-1514.
21. Wald A. Tests of Statistical Hypotheses concerning Several Parameters When the Number of Observations is Large. Trans Am Math Soc. 1943;54:426-482.
22. Sohani AR, Jaffe ES, Harris NL, Ferry JA, Pittaluga S, Hasserjian RP. Nodular lymphocytepredominant hodgkin lymphoma with atypical T cells: a morphologic variant mimicking peripheral T-cell lymphoma. Am J Surg Pathol. 2011;35 (11):1666-1678.
23. Koch K, Hoster E, Unterhalt M, et al. The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease. Hum Pathol. 2012;43 (12):2274-2281.
24. Adam P, Katzenberger T, Eifert M, et al. Presence of preserved reactive germinal centers in follicular lymphoma is a strong histopathologic indicator of limited disease stage. Am J Surg Pathol. 2005; 29 (12):1661-1664.
25. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian- Danish study. J Clin Oncol. 2007;25 (24): 3746-3752.
26. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91 (4): 475-481.
27. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008; 111 (1):109-111.
28. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003; 101 (11):4285-4289.
29. Fanale M, Lai C-M, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. ASH Annual Meeting Abstracts. 2010;Abstract 2812.